Applications of the Technology

Clinical Trials

NeuroVigil enables pharmaceutical companies to use EEG recordings to analyze drug efficacy and screen for biomarker data indicating neuropathologies.

The efficacy and effects of generic and sleep inducing drugs on brain activity can be seen in the biomarker data. Many drugs are known to affect sleep even though they may initially have been developed for other purposes. For example, anti-depressants, the most prescribed drugs in the U.S., are known to profoundly affect the latency and duration of REM sleep. Little is known about the effect of these and other drugs on high frequency components of brain activity, as these had been thought to be inaccessible by EEGs. A focus of NeuroVigil's clinical program is to assist drug companies in isolating hidden drug induced contaminations of brain activity, before these drugs are commercialized.


Two billion people worldwide are affected by a brain or nervous system disorder, including 100 million in America. NeuroVigil's non-invasive, wireless window into the brain maps brain activity and can offer insight into the diagnosis and treatment of conditions such as Alzheimer's, autism, cancer, epilepsy, depression, and schizophrenia. NeuroVigil technology is currently utilized in major universities and pharmaceutical companies to provide brain analyses of subjects throughout research studies and trials.

Sleep Studies

Seventy million Americans have sleep disorders causing apnea, fatigue, depression, and minor to severe accidents. These disorders can also be indicators of disease or trauma. NeuroVigil's technologic advance dramatically improves the quality and lowers the costs of sleep testing. Our technology not only automates current manual tasks, but also more than quadruples the amount of useful information obtained from current EEG data, which leads to neural signatures, or correlates of important disease states, that are useful in early detection and diagnosis of important medical conditions.